Saturday 17 October 2026
Export OABI’s income statement to Excel — free account
OmniAb, Inc.
OABI Healthcare Biotechnology
OmniAb, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $18.7 million, down 29.3% from fiscal 2024. In the quarter to June 2026, revenue grew 244.2%, EPS grew 66.7% and free cash flow grew 211.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
4.59
0.14
−2.96%
Follow OABI
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
8.24 | 6.96 | 11.26 | 8.70 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
118.27 | (40.97) | (37.05) | (18.80) | |
P/B ratio |
1.22 | 0.77 | 0.79 | 0.66 | |
Price to Tangible BV |
5.26 | 3.38 | 3.63 | 2.82 | |
EV/Sales |
6.89 | 5.26 | 8.37 | 5.88 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(14.99) | (5.97) | (4.28) | (3.58) | |
EV/FCF |
(14.60) | (6.61) | (4.59) | (3.85) | |
Quick Ratio |
4.53 | 4.55 | 3.78 | 4.71 | |
Current Ratio |
4.80 | 4.80 | 4.02 | 5.00 | |
Net Debt/EBITDA |
20.28 | 60.29 | 6.51 | 4.36 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.13 | 0.10 | 0.06 | 0.07 | |
Operating CF/Net income |
(0.46) | 0.64 | 0.40 | 0.59 | |
Capex/Depreciation |
(0.03) | (0.02) | 0.00 | (0.04) | |
Research and Development Expense of Revenue |
71.46% | 66.82% | 166.06% | 463.56% | |
Selling, General and Administrative Expense of Revenue |
49.59% | 45.88% | 81.65% | 302.68% | |
Intangible Assets out of Total Assets |
0.69 | 0.69 | 0.70 | 0.69 | |
Share Based Compensation of Revenue |
23.55% | 23.15% | 43.05% | 177.00% | |
Graham Net Nets |
0.11 | 0.17 | 0.15 | 0.19 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(14.63%) | (29.30%) | (30.81%) | (36.25%) | |
Free Cash Flow Yield |
(5.73%) | (11.43%) | (16.18%) | (17.57%) | |
Revenue per Share |
0.10 | 0.11 | 0.07 | 0.02 | |
Operating CF per Share |
0.02 | (0.04) | (0.05) | (0.09) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.02 | (0.04) | (0.05) | (0.09) | |
Cash per Share |
0.40 | 0.38 | 0.48 | 0.52 | |
Shareholders Equity per Share |
2.02 | 2.05 | 2.35 | 2.42 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.02 | 2.05 | 2.35 | 2.42 | |
Free Cash Flow |
2.57 | (5.08) | (5.68) | (9.94) | |
Working Capital |
52.26 | 51.56 | 49.09 | 53.07 | |
Capital Expenditures |
(0.11) | (0.17) | (0.01) | (0.18) | |
Net Current Asset Value |
36.03 | 34.12 | 31.45 | 34.10 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.01 | 0.00 | 0.08 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
6.52 | 9.56 | 6.33 | 3.30 | |
Average Payables |
2.03 | 1.79 | 2.09 | 2.05 | |
Average Assets |
292.97 | 299.92 | 313.24 | 320.62 | |
Average Common Equity |
261.17 | 268.08 | 277.32 | 284.59 |
Columns are period end dates